113 related articles for article (PubMed ID: 15307917)
1. The relationship between nevirapine plasma concentrations and abnormal liver function tests.
Almond LM; Boffito M; Hoggard PG; Bonora S; Raiteri R; Reynolds HE; Garazzino S; Sinicco A; Khoo SH; Back DJ; Di Perri G
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):716-22. PubMed ID: 15307917
[TBL] [Abstract][Full Text] [Related]
2. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
De Requena DG; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2005 Jun; 21(6):555-9. PubMed ID: 15989460
[TBL] [Abstract][Full Text] [Related]
3. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Núñez M; González-Requena D; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
[TBL] [Abstract][Full Text] [Related]
6. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
[TBL] [Abstract][Full Text] [Related]
8. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
[TBL] [Abstract][Full Text] [Related]
9. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Pineda JA;
HIV Clin Trials; 2012; 13(2):61-9. PubMed ID: 22510353
[TBL] [Abstract][Full Text] [Related]
10. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Barreiro P; Rodríguez-Novoa S; Labarga P; Ruiz A; Jiménez-Nácher I; Martín-Carbonero L; Gonzalez-Lahoz J; Soriano V
J Infect Dis; 2007 Apr; 195(7):973-9. PubMed ID: 17330787
[TBL] [Abstract][Full Text] [Related]
11. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.
Seminari E; Gentilini G; Galli L; Hasson H; Danise A; Carini E; Dorigatti F; Soldarini A; Lazzarin A; Castagna A
J Antimicrob Chemother; 2005 Oct; 56(4):790-2. PubMed ID: 16143711
[TBL] [Abstract][Full Text] [Related]
12. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
Palmon R; Koo BC; Shoultz DA; Dieterich DT
J Acquir Immune Defic Syndr; 2002 Apr; 29(4):340-5. PubMed ID: 11917237
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ
Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.
Rakhmanina NY; Capparelli EV; van den Anker JN; Williams K; Sever JL; Spiegel HM; Soldin SJ
Ther Drug Monit; 2007 Feb; 29(1):110-7. PubMed ID: 17304158
[TBL] [Abstract][Full Text] [Related]
15. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
[TBL] [Abstract][Full Text] [Related]
16. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
[TBL] [Abstract][Full Text] [Related]
17. Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.
Kou H; Du X; Li Y; Xie J; Qiu Z; Ye M; Fu Q; Han Y; Zhu Z; Li T
PLoS One; 2013; 8(1):e52950. PubMed ID: 23359265
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
Wongtrakul J; Thongtan T; Roytrakul S; Kumrapich B; Janphen K; Praparattanapan J; Supparatpinyo K; Smith DR
Dis Markers; 2014; 2014():315824. PubMed ID: 25580050
[TBL] [Abstract][Full Text] [Related]
20. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
